Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
China Approvals Clinical Trials

Could New Data Herald China Approval For Comirnaty?

  • Analysis

Executive Summary

Long-term safety results from the mRNA COVID-19 vaccine’s Phase II trial in a Chinese population could pave the way for its approval in China, investigators say.

You may also be interested in...



China's mRNA Shot Shows Benefits Over Older COVID Vaccines

Home-grown Chinese mRNA COVID-19 vaccines are more effective than domestic inactivated virus-based shots, new trial results show.

Facing COVID Surge, China Revises Course To Support Imported mRNA Vaccines

Latest announcement from Shanghai government set to open foreign mRNA jabs to the arms of Chinese people, after months of stalling approvals.

New Modalities Help Chinese Biotechs Win Investors’ Attention

Five Chinese bioventures have raised more than $70m from venture capital and private equity funds since late May.

Table

View full table

Topics

Related Companies

Tags:
China Approvals Clinical Trials
Latest News

It’s Coming Home: ImmunoACT Advances Plans For Cut-Price CAR-T In India

J&J’s Gorsky Offers Leadership Lessons As He Gets Set To Advise Apple

China Relaxes Restrictions Amid 'Zero' Severe Shanghai Cases

ARCH Cites Stability Of Long-Term Investors In Raising $3bn Fund

UsernamePublicRestriction

Register

SC146474

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By